Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study.

2.50
Hdl Handle:
http://hdl.handle.net/10541/240452
Title:
Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study.
Authors:
Czuczman, M; Fayad, L; Delwail, V; Cartron, G; Jacobsen, E; Kuliczkowski, K; Link, B; Pinter-Brown, L; Radford, John A ( 0000-0001-7898-2786 ) ; Hellmann, A; Gallop-Evans, E; DiRienzo, C; Goldstein, N; Gupta, I; Jewell, R; Lin, T; Lisby, S; Schultz, M; Russell, C; Hagenbeek, A
Abstract:
New treatments are required for rituximab-refractory follicular lymphoma (FL). In the present study, patients with rituximab-refractory FL received 8 weekly infusions of ofatumumab (CD20 mAb; dose 1, 300 mg and doses 2-8, 500 or 1000 mg; N = 116). The median age of these patients was 61 years, 47% had high-risk Follicular Lymphoma International Prognostic Index scores, 65% were chemotherapy-refractory, and the median number of prior therapies was 4. The overall response rate was 13% and 10% for the 500-mg and 1000-mg arms, respectively. Among 27 patients refractory to rituximab monotherapy, the overall response rate was 22%. The median progression-free survival was 5.8 months. Forty-six percent of patients demonstrated tumor reduction 3 months after therapy initiation, and the median progression-free survival for these patients was 9.1 months. The most common adverse events included infections, rash, urticaria, fatigue, and pruritus. Three patients experienced grade 3 infusion-related reactions, none of which were considered serious events. Grade 3-4 neutropenia, leukopenia, anemia, and thrombocytopenia occurred in a subset of patients. Ofatumumab was well tolerated and modestly active in this heavily pretreated, rituximab-refractory population and is therefore now being studied in less refractory FL and in combination with other agents in various B-cell neoplasms. The present study was registered at www.clinicaltrials.gov as NCT00394836.
Affiliation:
Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
Citation:
Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. 2012, 119 (16):3698-704 Blood
Journal:
Blood
Issue Date:
19-Apr-2012
URI:
http://hdl.handle.net/10541/240452
DOI:
10.1182/blood-2011-09-378323
PubMed ID:
22389254
Type:
Article
Language:
en
ISSN:
1528-0020
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorCzuczman, Men_GB
dc.contributor.authorFayad, Len_GB
dc.contributor.authorDelwail, Ven_GB
dc.contributor.authorCartron, Gen_GB
dc.contributor.authorJacobsen, Een_GB
dc.contributor.authorKuliczkowski, Ken_GB
dc.contributor.authorLink, Ben_GB
dc.contributor.authorPinter-Brown, Len_GB
dc.contributor.authorRadford, John Aen_GB
dc.contributor.authorHellmann, Aen_GB
dc.contributor.authorGallop-Evans, Een_GB
dc.contributor.authorDiRienzo, Cen_GB
dc.contributor.authorGoldstein, Nen_GB
dc.contributor.authorGupta, Ien_GB
dc.contributor.authorJewell, Ren_GB
dc.contributor.authorLin, Ten_GB
dc.contributor.authorLisby, Sen_GB
dc.contributor.authorSchultz, Men_GB
dc.contributor.authorRussell, Cen_GB
dc.contributor.authorHagenbeek, Aen_GB
dc.date.accessioned2012-08-29T15:33:37Z-
dc.date.available2012-08-29T15:33:37Z-
dc.date.issued2012-04-19-
dc.identifier.citationOfatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. 2012, 119 (16):3698-704 Blooden_GB
dc.identifier.issn1528-0020-
dc.identifier.pmid22389254-
dc.identifier.doi10.1182/blood-2011-09-378323-
dc.identifier.urihttp://hdl.handle.net/10541/240452-
dc.description.abstractNew treatments are required for rituximab-refractory follicular lymphoma (FL). In the present study, patients with rituximab-refractory FL received 8 weekly infusions of ofatumumab (CD20 mAb; dose 1, 300 mg and doses 2-8, 500 or 1000 mg; N = 116). The median age of these patients was 61 years, 47% had high-risk Follicular Lymphoma International Prognostic Index scores, 65% were chemotherapy-refractory, and the median number of prior therapies was 4. The overall response rate was 13% and 10% for the 500-mg and 1000-mg arms, respectively. Among 27 patients refractory to rituximab monotherapy, the overall response rate was 22%. The median progression-free survival was 5.8 months. Forty-six percent of patients demonstrated tumor reduction 3 months after therapy initiation, and the median progression-free survival for these patients was 9.1 months. The most common adverse events included infections, rash, urticaria, fatigue, and pruritus. Three patients experienced grade 3 infusion-related reactions, none of which were considered serious events. Grade 3-4 neutropenia, leukopenia, anemia, and thrombocytopenia occurred in a subset of patients. Ofatumumab was well tolerated and modestly active in this heavily pretreated, rituximab-refractory population and is therefore now being studied in less refractory FL and in combination with other agents in various B-cell neoplasms. The present study was registered at www.clinicaltrials.gov as NCT00394836.en_GB
dc.language.isoenen
dc.rightsArchived with thanks to Blooden_GB
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAged, 80 and over-
dc.subject.meshAntibodies, Monoclonal-
dc.subject.meshAntibodies, Monoclonal, Murine-Derived-
dc.subject.meshAntineoplastic Agents-
dc.subject.meshB-Lymphocytes-
dc.subject.meshDisease-Free Survival-
dc.subject.meshDrug Resistance, Neoplasm-
dc.subject.meshHumans-
dc.subject.meshLymphoma, Follicular-
dc.subject.meshMiddle Aged-
dc.subject.meshPrognosis-
dc.subject.meshProspective Studies-
dc.titleOfatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.en_GB
dc.identifier.journalBlooden_GB

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.